

Phoenix International Life Sciences Incorporated

[View the current Phoenix International Life Sciences Incorporated Page on BioPortfolio.com](http://www.bioportfolio.com/biocorporate/8329-Phoenix+International+Life+Sciences+Incorporated.html)

(<http://www.bioportfolio.com/biocorporate/8329-Phoenix+International+Life+Sciences+Incorporated.html>)

Contact Details:

2350 Cohen Street
Saint-Laurent
Quebec
H4R 2N6
Canada

Tel: 514 333 0033
Fax: 514 333 8861
Email: info@pils.com

Phoenix International is a global leader in early stage pharmaceutical development and has a growing presence in late stage pharmaceutical development.

Recent Publications by Phoenix International Life Sciences Incorporated:



- [Controlled, multidose, pharmacokinetic evaluation of two extended-release carbamazepine formulations \(Carbatrol and Tegretol-XR\).](#)
*A major limitation of conventional carbamazepine (CBZ) formulations is...*19th July, 2000
Phoenix International Life Sciences, Inc., Cincinnati, Ohio 45224, USA.- J Pharm Sci. 1998 Dec;87(12):1531-4.
- [In vivo pharmacokinetic screening in cassette dosing experiments; the use of on-line Pprospekt liquid chromatography/atmospheric pressure chemical ionization tandem mass spectrometry technology in drug discovery.](#)
*Drug discovery is a fast growing field and the number of compounds...*20th June, 2000
Advanced Analytical Research and Development Department, Phoenix- Rapid Commun Mass Spectrom. 1998;12(17):1216-22. ([DOI Direct Link](#))

Press Releases on Phoenix International Life Sciences Incorporated:

River Blindness (Onchocerciasis) Reduced By Nearly One-Third In At-Risk Populations In Six Countries	21st November, 2009	American Society of Tropical Medicine and Hygiene	WASHINGTON, Nov. 21 /PRNewswire-USNewswire/ -- A regional initiative launched in the 1990s to eliminate onchocerciasis (river blindness) in the Americas has substantially reduced the prevalence of the
Senate Poised to Advance Majority Leader Reid's Anti-Life Bill	21st November, 2009	Americans United for Life Action	AUL Action Campaign: Vote NO on Cloture "This bill provides for unprecedented expansion of federally-funded abortion. Real health care respects life, not ends it." Charmaine Yoest
H1N1 Pandemic May Have Peaked in October in U.S., According to Quest Diagnostics	20th November, 2009	Quest Diagnostics Incorporated	-- Rates of positive test results for the pandemic have declined in recent weeks in most regions, with the exception of the Northeast, where rates have more than doubled during
Counselors Address Mental-Health Crisis in Developing Countries	20th November, 2009	Wake Forest University	WINSTON-SALEM, N.C., Nov. 20 /PRNewswire-USNewswire/ -- Worldwide, more than 450 million people live with unmet mental health care needs. Wake Forest University Counseling Professor Donna Henderson co
Case Studies Offer Inside Look at Effective Ways to Address Global Health Challenges	20th November, 2009	Alliance for Case Studies for Global Health	Publication to Serve as Guide to Understanding, Building Productive Partnerships WASHINGTON, Nov. 20 /PRNewswire-USNewswire/ -- Meaningful and lasting progress in addressing global health challenges

Phoenix International Life Sciences Incorporated Clinical Trials:



- [Bioavailability Study of \(Buspar\) Buspirone HCl Tablets Under Fasting Conditions](#)



Phoenix International Life Sciences Incorporated Patents:

- 5658800- [Method for extraction, using extraction cartridge and automated extraction processing system](#)
- 5603160- [Method for making an extraction cartridge](#)
- 5598933- [Method for extraction, extraction cartridge and automated extraction processing system](#)
- 5585070- [Method for extraction, extraction cartridge and automated extraction processing system](#)

BioCorporate Profiles - upgrade to a full profile

BioPortfolio's BioCorporate full profiles offers your organization the opportunity to increase internet traffic to your corporate web site and enhance awareness of your business, technology, products and services. BioCorporate profiles are dynamic and are updated weekly with new information sourced from core information resources: publications, clinical trials, patents and global news.

Why you should upgrade your BioPortfolio BioCorporate profile:

- the ability to amend and add information on products and services to your profile using a membership username and password
- the option to add a corporate logo
- the creation of high value URL links back to your organization's website which will improve search engine ranking - resulting in increased site traffic
- the option have your press releases published on BioPortfolio and distributed via our BioNewsCast service
- an enhanced BioCorporate profile will also improve your exposure on BioPortfolio's related service InDepth and GeneDB

The annual cost is \$995.00 for established organizations and \$495.00 for organizations less than 12 months old.

Resources from the [NCBI](#) used in this document, [NCBI's standard disclaimer applies](#).

Nothing in this document should be used in place of personal medical advice from your own qualified medical practitioner. See BioPortfolio.com [User Agreement](#)

Send comments and feedback to:

Peter Barfoot Managing Director, BioPortfolio Ltd.

UK Tel: (+44) 1300 321501

USA Voicemail and Fax: (+1) 415 680 2472

[Peter Barfoot peter.barfoot@bioportfolio.com](mailto:peter.barfoot@bioportfolio.com)

All rights reserved. All other trademarks recognized.

BioPortfolio Limited is registered in England & Wales at Stafford House, 10 Prince of Wales Road, Dorchester, Dorset, DT1 1PW, UK. No.3312883 VAT No. GB 744 6483 10

Copyright 1997-2009 - BioPortfolio Limited.

